A Partner in Health
A new chapter, a new approach. Collaborating with physicians and other healthcare professionals, focusing on R&D and maintaining clinical leadership add up to innovative medical solutions that make a difference.
Work with Us
Join Covidien, where we appreciate your talent, your experience and your passion for your work. Our culture thrives because we invest in our colleagues' growth and reward their efforts.
Visit Us
Covidien will be at the Association for Professionals in Infection Control and Epidemiology in Ft. Lauderdale from June 7 – 11, 2009
Covidien Medical Supplies will be at the Medical Design and Manufacturing East in New York from June 9 – 11, 2009
Covidien Respiratory will be at the Associated Professional Sleep Societies in Seattle from June 6 - 11, 2009
COV (NYSE)
| Price: | $45.65 |
| Change: | 0.52 |
| Volume: | 3,393,675 |
Minimum 20 minute delay
-
11/20/2009 7:31:00 AM
FDA Extends Review of NDA for Exalgo(TM)
ST. LOUIS--(BUSINESS WIRE)--Nov. 20, 2009-- Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) has set a new action date under the Prescription Drug User Fee Act for the review of the New Drug Application (NDA) for Exalgo™ (hydromorphone HCl extended-release) Tablets (CII), (Exalgo) of … -
11/17/2009 6:01:00 AM
Covidien Reports Fourth-Quarter and Fiscal 2009 Results
Fourth-quarter diluted GAAP earnings per share from continuing operations were $0.11; excluding specified items, adjusted diluted earnings per share from continuing operations were $0.72 Fiscal 2009 diluted GAAP earnings per share from continuing operations were … -
11/16/2009 7:31:00 AM
FDA Discusses Neuromed NDA Application for Exalgo
MANSFIELD, Mass.--(BUSINESS WIRE)--Nov. 16, 2009-- Covidien (NYSE: COV) today announced that on November 13, 2009, representatives of Neuromed discussed the pending New Drug Application (NDA) for the product candidate ExalgoTM (hydromorphone HCl extended release) tablets with staff from the … -
11/11/2009 4:30:00 PM
Covidien Introduces First FDA-Approved Spine Sealant
Fast-acting DuraSeal™ spine sealant provides critical watertight seal during spine surgery NORTH HAVEN, Conn.--(BUSINESS WIRE)--Nov. 11, 2009-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of DuraSeal™ spine sealant, the first product approved by the …